Enlivex Therapeutics Stock Set to Reverse Split on Tuesday, October 27th (NASDAQ:ENLV)

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s stock is going to reverse split on the morning of Tuesday, October 27th. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, October 26th.

Enlivex Therapeutics Price Performance

Shares of NASDAQ ENLV traded down $0.03 during mid-day trading on Friday, reaching $0.17. 655,132 shares of the company’s stock traded hands, compared to its average volume of 364,410. The stock has a market cap of $3.03 million, a P/E ratio of -0.02 and a beta of 1.42. The business has a 50-day simple moving average of $0.79 and a 200 day simple moving average of $6.06. Enlivex Therapeutics has a 1-year low of $0.17 and a 1-year high of $27.15.

Wall Street Analysts Forecast Growth

ENLV has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Finally, Zacks Research downgraded Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $247.50.

Hedge Funds Weigh In On Enlivex Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. WINTON GROUP Ltd bought a new position in shares of Enlivex Therapeutics in the second quarter valued at approximately $55,000. Susquehanna International Group LLP increased its position in shares of Enlivex Therapeutics by 1,428.5% during the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after acquiring an additional 147,334 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in Enlivex Therapeutics by 53.2% during the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after acquiring an additional 45,303 shares during the period. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company developing immunotherapies designed to restore immune-system balance in conditions associated with excessive or dysregulated inflammation. The company is based in Israel and trades on the Nasdaq under the symbol ENLV.

Enlivex’s lead product candidate is Allocetra, an investigational, off-the-shelf cell therapy intended to reprogram immune cells known as macrophages and promote immune homeostasis. The therapy is being studied as a potential treatment for severe inflammatory conditions, including sepsis and osteoarthritis of the knee.

The company’s clinical development activities have included studies in Israel and other locations, with programs focused on evaluating Allocetra’s safety and potential efficacy.